ATXS - Astria Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$19.40
DETAILS
HIGH:
$26.00
LOW:
$13.00
MEDIAN:
$20.00
CONSENSUS:
$19.40
UPSIDE:
54.21%
About Astria Therapeutics, Inc. (https://www.astriatx.com)
Astria Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, established in 2008. The firm specializes in identifying, advancing, and bringing to market treatments for uncommon and specialized allergic and immunological disorders across the United States. Its leading experimental drug, STAR-0215, is a monoclonal antibody that targets and inhibits plasma kallikrein. This candidate is presently undergoing preclinical development to address hereditary angioedema. The company adopted its current name, Astria Therapeutics, Inc., in September 2021, having previously operated as Catabasis Pharmaceuticals, Inc.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Jill C. Milne | Co-Founder, Chief Executive Officer, President & Director | 1968 | $967,338 USD |
| Christopher J. Morabito | Chief Medical Officer | 1970 | $690,824 USD |
| Benjamin S. Harshbarger | Chief Legal Officer | 1969 | $658,041 USD |
| Noah Clauser | Chief Financial Officer & Treasurer | 1973 | $621,406 USD |
| Andrea L. Matthews | Chief Business Officer | 1982 | – |
| Andrew A. Komjathy | Chief Commercial Officer | 1963 | – |
| John Ruesch | Senior Vice President of Pharmaceutical Sciences & Technical Operations | – | – |
| Keri McGrail | Chief Human Resources Officer | – | – |
| Rafif Dagher | Senior Vice President and Head of Discovery, Nonclinical Development & Translational Research | – | – |